439 related articles for article (PubMed ID: 21771280)
1. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.
Azzouni F; Abu samra K
J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280
[TBL] [Abstract][Full Text] [Related]
2. [Non-arteritic anterior ischemic optic neuropathy associated with erectile dysfunction medications].
Krashin-Bichler I; Dotan G
Harefuah; 2013 Feb; 152(2):84-7, 123. PubMed ID: 23513498
[TBL] [Abstract][Full Text] [Related]
3. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?
Aliferis K; Petropoulos IK; Farpour B; Matter MA; Safran AB
Ophthalmologica; 2012; 227(2):85-9. PubMed ID: 22156704
[TBL] [Abstract][Full Text] [Related]
4. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction.
Laties A; Sharlip I
J Sex Med; 2006 Jan; 3(1):12-27. PubMed ID: 16409214
[TBL] [Abstract][Full Text] [Related]
5. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
7. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Lowe G; Costabile RA
J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
[TBL] [Abstract][Full Text] [Related]
8. Sildenafil-associated consecutive nonarteritic anterior ischaemic optic neuropathy, cilioretinal artery occlusion, and central retinal vein occlusion in a haemodialysis patient.
Gedik S; Yilmaz G; Akova YA
Eye (Lond); 2007 Jan; 21(1):129-30. PubMed ID: 16732206
[No Abstract] [Full Text] [Related]
9. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)].
Calvet C; Martin K; Robert G; Moore N; Eftekhari P; Farghal H; Molimard M; Ballanger P
Prog Urol; 2007 Sep; 17(5):920-7. PubMed ID: 17969789
[TBL] [Abstract][Full Text] [Related]
11. Optic atrophy after sildenafil use.
Sowka JW; Neiberg MN; Vollmer LA
Optometry; 2007 Mar; 78(3):122-8. PubMed ID: 17321461
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil-associated vascular CASUALTIES.
Oguz H
Eye (Lond); 2007 May; 21(5):676-7; author reply 677-8. PubMed ID: 17187028
[No Abstract] [Full Text] [Related]
13. Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case.
El-Domyati MM; El-Fakahany HM; Morad KE
Andrologia; 2009 Oct; 41(5):319-21. PubMed ID: 19737280
[TBL] [Abstract][Full Text] [Related]
14. Recurrent uveitis due to sildenafil usage in a patient with Behçet's disease.
Işık M; Kılıç L; Doğan I
Rheumatol Int; 2013 Mar; 33(3):803. PubMed ID: 22095394
[TBL] [Abstract][Full Text] [Related]
15. Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra.
Akash R; Hrishikesh D; Amith P; Sabah S
J Ocul Pharmacol Ther; 2005 Aug; 21(4):315-7. PubMed ID: 16117695
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
Kamenov ZA
J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
[TBL] [Abstract][Full Text] [Related]
17. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
[TBL] [Abstract][Full Text] [Related]
19. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy.
Pomeranz HD; Smith KH; Hart WM; Egan RA
Ophthalmology; 2002 Mar; 109(3):584-7. PubMed ID: 11874765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
